AbbVie preps filings after ABBV-951 tops oral Parkinson’s drugs in trial

AbbVie has reported that a subcutaneous infusion of Parkinson’s disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory filings.